JNJ

Pfizer, Merck and Johnson & Johnson shifting profits to avoid billions in tax payments each year: report
Pfizer, Merck and Johnson & Johnson shifting profits to avoid billions in tax payments each year: report
Fierce Pharma
taxes
Pfizer
Merck
JNJ
Abbott Labs
Flag link:
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Yahoo/Zacks.com
JNJ
erdafitinib
urothelial cancer
Flag link:
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617
Flag link:
J&J execs say new launches and label expansions will fuel 'above-market' growth through 2021
J&J execs say new launches and label expansions will fuel 'above-market' growth through 2021
Fierce Pharma
JNJ
label expansions
esketamine
erdafitinib
Flag link:
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Johnson & Johnson Seeks EU and US Label Expansion for Darzalex
Market Realist
JNJ
Janssen
Darzalex
daratumumab
Europe
Multiple Myeloma
Flag link:
J&J acquires 3D-printed spinal implant maker EIT
J&J acquires 3D-printed spinal implant maker EIT
Mass Device
JNJ
devices
spinal fusion
Emerging Implant Technologies
EIT
M&A
Flag link:
Johnson & Johnson raises a flag in early-stage lung cancer with first-ever contest in the field
Johnson & Johnson raises a flag in early-stage lung cancer with first-ever contest in the field
Fierce Pharma
JNJ
innovation
R&D
lung cancer
drug development
Flag link:
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
CP Wire
Janssen Pharmaceuticals
JNJ
chronic plaque psoriasis
Tremfya
Humira
AbbVie
clinical trials
Flag link:
Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira
Janssen Pharmaceuticals
JNJ
chronic plaque psoriasis
Tremfya
Humira
Flag link:
India Orders Payments From J&J’s DePuy Over ‘Faulty’ Hip Implants
India Orders Payments From J&J’s DePuy Over ‘Faulty’ Hip Implants
RAPS.org
India
DePuy
JNJ
hip implants
Flag link:
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week
Motley Fool
Amarin
CRISPR Therapeutics
Geron
Vascepa
Vertex Pharmaceuticals
CTX001
JNJ
imetelstat
Flag link:
Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid
Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid
CNBC
depression
ketamine
opioids
JNJ
Allergan
Flag link:
ESC 2018 – J&J not downhearted after Xarelto stumbles
ESC 2018 – J&J not downhearted after Xarelto stumbles
EP Vantage
ESC 2018
JNJ
Xarelto
bloodthinner
Flag link:
Johnson & Johnson Is Hiring -- and It's Ginormous News for Geron
Johnson & Johnson Is Hiring -- and It's Ginormous News for Geron
Yahoo/Motley Fool
JNJ
Geron
hirings
imetelstat
Imbruvica
Flag link:
ESC 2018 – Xarelto again fails to Command an advantage
ESC 2018 – Xarelto again fails to Command an advantage
EP Vantage
JNJ
Bayer
Xarelto
ESC 2018
Flag link:
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Endpoints
AbbVie
JNJ
FDA
Imbruvica
Rituxan
Roche
AstraZeneca
non-Hodgkin's lymphoma
Waldenström’s macroglobulinemia
Flag link:
Pfizer lawsuit could clear path for biosimilars
Pfizer lawsuit could clear path for biosimilars
Medical Marketing and Media
Pfizer
JNJ
Remicade
biosimilars
Inflectra
Flag link:
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
RAPS.org
FDA
JNJ
Janssen
Lundbeck
Takeda
major depressive disorder
drug development
Flag link:
Should Gilead Be Worried About This New Monthly HIV Medication?
Should Gilead Be Worried About This New Monthly HIV Medication?
Motley Fool
Gilead Sciences
HIV
JNJ
ViiV
cabotegravir
rilpivirine
Edurant
Flag link:
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
RAPS.org
Pfizer
JNJ
Remicade
biosimilars
Inflectra
Flag link:

Pages